SEC Form 4 · accession 0001104659-18-044168
SYNERGY PHARMACEUTICALS, INC. · SGYP
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Thomas Adams Ph.D.
Director
Period of report
Jul 3, 2018
Accepted (ET)
Jul 6, 2018 · 4:31 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001347613
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jul 3, 2018 | M | 100,023 | $0.50 | A | 100,023 | D | |
| Common StockF1 | Jul 3, 2018 | F | 27,785 | $0.00 | D | 72,238 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock OptionsF2 | $0.50 | Jul 3, 2018 | M | 100,023 | D | — | Jul 9, 2018 | Common Stock | 100,023 | 434,223 | D |
Explanation of responses
- F1Represents the number of shares forfeited to the Company in payment of the exercise price of the stock options.
- F2Options became exercisable on 7/9/2009 and 7/9/2010.